Lon Onc News Today

Oncimmune Holdings plc (LON:ONC – Get Free Report) dropped 3.1% on Monday . The company traded as low as GBX 25.20 ($0.32) and last traded at GBX 25.20 ($0.32). Approximately 8,242 shares were traded during trading, a decline of 92% from the average daily volume of 106,396 shares. The stock had previously closed at GBX […]

Oncimmune Holdings plc (LON:ONC – Get Free Report)’s stock price fell 6.6% on Thursday . The company traded as low as GBX 17.80 ($0.22) and last traded at GBX 17.80 ($0.22). 71,788 shares were traded during mid-day trading, a decline of 37% from the average session volume of 114,696 shares. The stock had previously closed […]

Oncimmune Holdings plc (LON:ONC – Get Free Report)’s share price reached a new 52-week low during trading on Friday . The stock traded as low as GBX 13 ($0.17) and last traded at GBX 16.10 ($0.21), with a volume of 106092 shares traded. The stock had previously closed at GBX 16.45 ($0.21). Oncimmune Trading Down […]

Oncimmune Holdings plc (LON:ONC – Get Rating) reached a new 52-week low during trading on Wednesday . The company traded as low as GBX 17 ($0.21) and last traded at GBX 17 ($0.21), with a volume of 177121 shares trading hands. The stock had previously closed at GBX 20 ($0.25). Oncimmune Trading Down 15.0 % […]

Oncimmune Holdings plc (LON:ONC – Get Rating) insider Adam Hill acquired 48,370 shares of the firm’s stock in a transaction dated Monday, June 5th. The stock was purchased at an average cost of GBX 21 ($0.26) per share, with a total value of £10,157.70 ($12,552.77). Oncimmune Stock Performance Shares of LON ONC traded up GBX […]

Oncimmune Holdings plc (LON:ONC – Get Rating) shares crossed below its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of GBX 40.19 ($0.50) and traded as low as GBX 37.40 ($0.47). Oncimmune shares last traded at GBX 37.40 ($0.47), with a volume of 1,636 shares trading […]

Director Deals - (ONC)

6 April 2021 | 07:44am StockMarketWire.com - Immunodiagnostics group Oncimmune said it had signed two separate agreements with Roche Pharmaceuticals and Cedars-Sinai Medical Center for use of the companys newly developed infectious disease panel. Oncimmune had in October announced the award of UK government funding for the development and validation of an infectious disease NavigAID panel. Utilising the data from this and other work, the companys current SeroTag research panel has been tailored...

15 February 2021 | 07:54am StockMarketWire.com - Immunodiagnostics group Oncimmune posted a narrower first-half loss on the back of higher revenue and lower R&D spending. Pre-tax losses for the six months through November amounted to £2.8 million, compared to losses of £5.5 million year-on-year. Revenue rose to £1.8 million, up from £0.3 million. Oncimmune said it saw a marked increase in commercial activity as large pharmaceutical and biotech companies utilised its biomarker discovery plat...

Genostics remains Oncimmunes exclusive partner in China and continues to work closely with Oncimmune to gain market entry